- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Mercaptopurine (oral suspension)
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Mercaptopurine (oral suspension)
| EU orphan designation number: | EU/3/09/628
|
| Active ingredient: | Mercaptopurine (oral suspension) |
| Indication: | Treatment of acute lymphoblastic leukaemia |
| Sponsor: | Nova Laboratories Limited
Martin House, Gloucester Crescent, Wigston Leicester, LE18 4YL, United Kingdom |
| EU Centralised marketing authorisation: | A centralised EU marketing authorisation has been obtained under the name Xaluprine on 09/03/2012 with the number EU/1/11/727 |
Public summary of scientific opinion
EPAR
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 05/05/2009 | Orphan designation | EMEA/OD/114/08 | (2009)3527 of 30/04/2009 |
CONTACT
EU links
Directorate General Health & Consumers